Specifically, we asked if our platform was capable of detecting changes in the phosphorylation profile of proteins in glioma xenografts upon inhibition of c-Met signaling using a previously validated neutralizing anti-HGF monoclonal antibody (L2G7) [38]. The gene discussed is MET; the disease is glioma.